Molecular Identity Comparison
CJC-1295 with DAC vs without DAC
Evidence summary: CJC-1295 with Drug Affinity Complex is a long-acting GHRH analog designed for covalent albumin binding. The material commonly sold as CJC-1295 without DAC is modified GRF(1-29), a distinct tetrasubstituted peptide. Human multi-day pharmacokinetic findings belong to the DAC molecule and should not be transferred to the no-DAC product.
Key findings
- DAC changes molecular identity and produces prolonged albumin-linked exposure.
- The 2006 human trials studied CJC-1295 with DAC, not modified GRF(1-29).
- No published pharmacokinetic study of the exact commercial no-DAC molecule was identified.
Two names that should not be collapsed
CJC-1295 with DAC incorporates a reactive group that forms a covalent bond with albumin. Modified GRF(1-29) lacks that DAC group. They therefore differ in structure, molecular mass and expected exposure.
A product record, label or COA should identify the exact molecule rather than treating 'CJC-1295' as sufficient.
Evidence for the DAC molecule
Jetté and colleagues described the albumin-binding design in preclinical work. Teichman and colleagues then studied CJC-1295 with DAC in healthy adults and estimated a 5.8–8.1 day half-life with multi-day GH and IGF-I effects.
Those short, industry-sponsored studies measured pharmacokinetics and endocrine biomarkers. They did not establish long-term outcomes or validate no-DAC material.
Evidence gap for modified GRF(1-29)
No published human or animal pharmacokinetic study of the exact tetrasubstituted no-DAC molecule was identified. Frequently repeated half-life figures are therefore not treated here as measured evidence.
Data for native GRF(1-29), sermorelin or CJC-1295-DAC provide context, not interchangeable proof.
Ipamorelin combinations remain untested
Ipamorelin activates a different receptor pathway, which creates a mechanistic combination hypothesis. No published human study was identified that co-administered ipamorelin with either CJC form.
A blended vial ratio is a product specification, not a clinically optimized or validated regimen.
Continue to the full evidence guide
The full guide includes expanded study context, additional questions, handling notes and the complete reference list.
Review the CJC-1295 and ipamorelin evidence brief →Frequently asked questions
Is CJC-1295 without DAC the same molecule?
No. The no-DAC product commonly refers to modified GRF(1-29), which lacks CJC-1295's albumin-binding DAC group.
Can the DAC half-life be used for no-DAC material?
No. The multi-day human estimate belongs to CJC-1295 with DAC.
Is CJC-1295 plus ipamorelin proven synergistic?
No published human co-administration study was identified.
Primary references
- Jetté L, et al. Identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005. PubMed 15817669
- Teichman SL, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. PubMed 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006. PubMed 17018654
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed 9849822
Related research materials
Research Use Only. Products are sold for laboratory research and are not for human or veterinary use. This page summarises published literature and is not dosing or medical guidance.
